Tag: Seattle Genetics

Gilead Sciences GILD NASDAQ:GILD
Finance

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton
Finance

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel